CNBC Cures takes on rare diseases

Summary

The segment discusses CNBC Cures, CNBC's rare disease initiative, and follows up on viewer response. Joe Kernen explains SYNGAP1, a rare genetic disorder affecting his daughter Kaylee, including haploinsufficiency, synaptic effects, seizures, and possible gene therapy. Becky Quick asks about prognosis and timing, but no specific securities or investment recommendations are discussed.

• CNBC Cures focuses on rare disease and launched a related podcast, newsletter, and summit.
• Joe Kernen shared his family's experience with his daughter Kaylee's SYNGAP1 diagnosis.
• SYNGAP1 involves haploinsufficiency and impaired synapse function.
• Only about 1,707 cases have been identified globally, but the true population is likely larger.
• Gene therapy is described as a possible one-and-done solution.
• Earlier intervention is viewed as potentially more effective; time is described as critical.
• No stock, asset, or investment recommendation was made in the segment.